Phase 1 MRX1 Study Delivers Strong Headline Data

Ananda Pharma has successfully completed its Phase 1 pharmacokinetic study of MRX1 Oral Solution, with all study objectives met. The trial confirmed a favourable safety and tolerability profile across two dose levels in healthy volunteers, with no serious adverse events and no study discontinuations.